시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 사이토카인 기반 치료제 및 억제제 시장 보고서(2025년)
Cytokine-Based Therapies And Inhibitors Global Market Report 2025
상품코드 : 1810864
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,294,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,098,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,902,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

사이토카인 기반 치료제 및 억제제 시장 규모는 향후 몇 년 동안 안정적으로 성장할 것으로 예상됩니다. 2029년 연평균 성장률(CAGR)은 4.2%로 1,733억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 세계 인구의 고령화, 표적 치료제 채택 확대, 만성 염증성 질환의 유병률 증가, 임상시험 파이프라인 확대, 면역학 연구에 대한 정부 지원, 환자 결과와 안전성에 대한 관심 증가 등에 기인합니다. 이 기간 동안 주요 동향으로는 단백질 공학의 발전, 다중 사이토카인 억제제 개발, 신약개발에서의 인공지능 적용, 바이오마커 식별을 위한 차세대 시퀀서, 디지털 헬스 플랫폼의 통합, 안정성 향상을 위한 제제 기술 개선 등을 들 수 있습니다.

자가면역질환의 증가는 향후 사이토카인 기반 치료제 및 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 면역체계가 건강한 세포나 조직을 이물질로 오인하여 공격함으로써 발생합니다. 이러한 질병의 증가는 식습관의 변화, 특히 고도로 가공된 식품의 소비 증가와 관련이 있으며, 장내 세균총을 교란하고 면역 조절을 방해할 수 있습니다. 사이토카인 기반 치료제 및 억제제는 염증에 관여하는 특정 사이토카인을 표적으로 삼아 면역반응을 조절하여 자가면역질환 관리에 효과적입니다. 예를 들어, 2024년 11월 독일에 본사를 둔 헬스케어 정보 포털 Versorgungsatlas.de의 조사에 따르면, 2022년 보험 가입자 73,241,305명 중 6,304,340명이 적어도 한 가지 이상의 자가면역질환을 앓고 있으며, 유병률은 8.61%였습니다. 이처럼 자가면역질환 유병률의 증가는 사이토카인 기반 치료제 및 억제제 시장의 성장을 촉진하고 있습니다.

사이토카인 기반 치료제 및 억제제 시장의 주요 기업들은 바실러스 카르메트 겔린(BCG) 비반응성 비근육침윤성 방광암(NMIBC) 환자의 완전 반응 지속성을 높이고 재발률을 낮추기 위한 방광 내 사이토카인 유지 면역요법 등 혁신적인 치료법을 개발하고 있습니다. 개발 중입니다. 이 접근법에서는 면역 활성화 단백질을 방광에 직접 투여한 후 장기적으로 유지 투여하여 국소 면역 반응을 지속적으로 자극하여 종양의 재증식을 방지합니다. 예를 들어, 2024년 4월 미국 식품의약국(FDA)은 BCG와 병용하는 새로운 사이토카인 기반 치료제인 nogapendekin alfa inbakicept-pmln(Anktiva)을 승인했습니다. 안티바는 인터류킨 15(IL-15) 경로를 표적으로 하는 융합단백질로 작용하여 자연살해(NK) 세포, CD8 양성 T세포 등 CD122 양성 면역세포를 활성화합니다. 이 메커니즘은 IL-15와 같은 신호전달 단백질을 이용하여 신체의 면역 감시와 항종양 활성을 높이는 사이토카인 기반 치료의 원리를 반영합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Cytokine-based therapies and inhibitors are medical treatments designed to either stimulate or block cytokine activity-small proteins that regulate immune responses, inflammation, and cell communication. These therapies help manage various conditions like cancer, autoimmune diseases, and inflammatory disorders by modulating immune system functions.

The main categories of cytokine-based therapies and inhibitors include interleukins, tumor necrosis factor, epidermal growth factor, interferons, and chemokines. Interleukins are cytokine proteins produced by immune cells that play a key role in regulating immune responses, inflammation, and cell signaling. These treatments are applied across diverse areas such as cancer, inflammatory and immune disorders, infectious diseases, asthma and airway inflammation, among others. They are used by a range of end users including hospitals, clinics, research laboratories, academic institutions, specialty centers, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The cytokine-based therapies and inhibitors market research report is one of a series of new reports from The Business Research Company that provides cytokine-based therapies and inhibitors market statistics, including cytokine-based therapies and inhibitors industry global market size, regional shares, competitors with a cytokine-based therapies and inhibitors market share, detailed cytokine-based therapies and inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine-based therapies and inhibitors industry. The cytokine-based therapies and inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytokine-based therapies and inhibitors market size has grown steadily in recent years. It will grow from $140.66 billion in 2024 to $146.95 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth during the historic period can be linked to the increasing prevalence of autoimmune diseases, a rising incidence of cancer, an expanding burden of infectious diseases, heightened demand for personalized medicine, advancements in vaccine development, and greater awareness of immunotherapies.

The cytokine-based therapies and inhibitors market size is expected to see steady growth in the next few years. It will grow to $173.32 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth projected for the forecast period can be attributed to the aging global population, increased adoption of targeted therapies, a rising incidence of chronic inflammatory diseases, expansion of clinical trial pipelines, government backing for immunology research, and an increased focus on patient outcomes and safety. Key trends during this period include advancements in protein engineering, development of multi-cytokine inhibitors, application of artificial intelligence in drug discovery, next-generation sequencing for biomarker identification, integration of digital health platforms, and improved formulation technologies for enhanced stability.

The increasing incidences of autoimmune disorders are expected to drive the growth of the cytokine-based therapies and inhibitors market in the future. Autoimmune disorders occur when the immune system mistakenly attacks healthy cells and tissues, treating them as foreign threats. The rise in these disorders is linked to dietary changes, especially the higher consumption of highly processed foods, which can disrupt gut microbiota and impair immune regulation. Cytokine-based therapies and inhibitors work by modulating the immune response through targeting specific cytokines involved in inflammation, making them effective in managing autoimmune conditions. For example, in November 2024, a survey by Versorgungsatlas.de, a Germany-based healthcare information portal, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. Thus, the growing incidence of autoimmune disorders is fueling the growth of the cytokine-based therapies and inhibitors market.

Leading companies in the cytokine-based therapy and inhibitor market are developing innovative treatments such as intravesical cytokine maintenance immunotherapy, aimed at enhancing the durability of complete responses and reducing recurrence rates in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). This approach involves administering immune-activating proteins directly into the bladder, followed by long-term maintenance doses to continuously stimulate local immune responses and prevent tumor regrowth. For instance, in April 2024, the US Food and Drug Administration approved nogapendekin alfa inbakicept-pmln (Anktiva), a novel cytokine-based therapy used in combination with BCG. Anktiva functions as a fusion protein targeting the interleukin-15 (IL-15) pathway, activating CD122-positive immune cells such as natural killer (NK) cells and CD8-positive T cells. This mechanism reflects the principle of cytokine-based therapy, which uses signaling proteins like IL-15 to boost the body's immune surveillance and anti-tumor activity.

In February 2022, Equillium Inc., a US-based biotechnology company, acquired Bioniz Therapeutics Inc. for an undisclosed sum. Through this acquisition, Equillium expanded its immunology pipeline by obtaining access to Bioniz's proprietary portfolio of cytokine therapies targeting immune-inflammatory diseases and certain cancers, thereby strengthening its position in autoimmune and oncology treatment areas. Bioniz Therapeutics is a US-based biotech firm specializing in the discovery and development of selective cytokine inhibitors for immune-related disorders.

Major players in the cytokine-based therapies and inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc, Lonza Group AG, Cytiva, UCB S.A., Sartorius CellGenix GmbH, Biocon Limited, Bio-Techne Corporation, and Miltenyi Biotec B.V. & Co. KG.

North America was the largest region in the cytokine-based therapies and inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cytokine-based therapies and inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cytokine-based therapies and inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cytokine-based therapies and inhibitors market consists of revenues earned by entities providing services such as the development, manufacturing, and commercialization of cytokine-targeted drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine-based therapies and inhibitors market includes sales of products such as colony-stimulating factors, transforming growth factors, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cytokine-Based Therapies And Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cytokine-based therapies and inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cytokine-based therapies and inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cytokine-based therapies and inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cytokine-Based Therapies And Inhibitors Market Characteristics

3. Cytokine-Based Therapies And Inhibitors Market Trends And Strategies

4. Cytokine-Based Therapies And Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cytokine-Based Therapies And Inhibitors Growth Analysis And Strategic Analysis Framework

6. Cytokine-Based Therapies And Inhibitors Market Segmentation

7. Cytokine-Based Therapies And Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Cytokine-Based Therapies And Inhibitors Market

9. China Cytokine-Based Therapies And Inhibitors Market

10. India Cytokine-Based Therapies And Inhibitors Market

11. Japan Cytokine-Based Therapies And Inhibitors Market

12. Australia Cytokine-Based Therapies And Inhibitors Market

13. Indonesia Cytokine-Based Therapies And Inhibitors Market

14. South Korea Cytokine-Based Therapies And Inhibitors Market

15. Western Europe Cytokine-Based Therapies And Inhibitors Market

16. UK Cytokine-Based Therapies And Inhibitors Market

17. Germany Cytokine-Based Therapies And Inhibitors Market

18. France Cytokine-Based Therapies And Inhibitors Market

19. Italy Cytokine-Based Therapies And Inhibitors Market

20. Spain Cytokine-Based Therapies And Inhibitors Market

21. Eastern Europe Cytokine-Based Therapies And Inhibitors Market

22. Russia Cytokine-Based Therapies And Inhibitors Market

23. North America Cytokine-Based Therapies And Inhibitors Market

24. USA Cytokine-Based Therapies And Inhibitors Market

25. Canada Cytokine-Based Therapies And Inhibitors Market

26. South America Cytokine-Based Therapies And Inhibitors Market

27. Brazil Cytokine-Based Therapies And Inhibitors Market

28. Middle East Cytokine-Based Therapies And Inhibitors Market

29. Africa Cytokine-Based Therapies And Inhibitors Market

30. Cytokine-Based Therapies And Inhibitors Market Competitive Landscape And Company Profiles

31. Cytokine-Based Therapies And Inhibitors Market Other Major And Innovative Companies

32. Global Cytokine-Based Therapies And Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cytokine-Based Therapies And Inhibitors Market

34. Recent Developments In The Cytokine-Based Therapies And Inhibitors Market

35. Cytokine-Based Therapies And Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기